ASKA Pharmaceutical Holdings (4886) Key Financial Indicators

2130
-21-0.98%

20min DelayTrading Jan 16 14:28 JST

61.27BMarket Cap11.84P/E (Static)

4886 Free Cash Flow (FCF)

Interested in knowing about ASKA Pharmaceutical Holdings's free cash flow? The latest report shows it as --. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.

Currency: JPY

Quarterly

4886 Current Ratio

If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of ASKA Pharmaceutical Holdings shows that the company's current ratio is 2.47, indicating healthy liquidity.

Currency: JPY

Quarterly

4886 Quick Ratio

Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of ASKA Pharmaceutical Holdings, the quick ratio is 1.03, indicating that the company can meet its short-term debt obligations.

Currency: JPY

Quarterly

4886 Return on Equity (ROE)

Want to learn more about the financial health of ASKA Pharmaceutical Holdings? The latest ROE figure is 1.90%, indicating that the company has stable profitability.

Currency: JPY

Quarterly

4886 Return on Assets (ROA)

Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of ASKA Pharmaceutical Holdings, the total asset return on investment (ROA) is 1.22%.

Currency: JPY

Quarterly

4886 Gross Margin

Gross margin can provide insight into a company's pricing strategy and cost structure. Check ASKA Pharmaceutical Holdings's latest financial report to see how their gross margin is doing - currently at 48.91%.

Currency: JPY

Quarterly

4886 Net Margin

For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of ASKA Pharmaceutical Holdings, the net profit margin is 7.62%, which is a good sign for its profitability.

Currency: JPY

Quarterly

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"